Cmax

Максимальная концентрация.

Навигация по записям

Следующая запись: биоэквивалентность

Найти:

Свежие записи

Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0
ClinicalTrialUtilities: обзор
Подборка полезной литературы – часть 2

Галерея

FDA Seeks to Engage Stakeholders on Key Considerations for a Drug Quality Management Maturity Program
Source: FDA - What's New: Drugs RSS Feed Published on 2022-05-17 By FDA
Center for Biologics Evaluation and Research Patient Engagement Program
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-05-17 By FDA
COVID-19 Vaccines
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-05-17 By FDA
Labeling for CBER-Regulated Products
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-05-17 By FDA
What's New Related to Drugs
Source: FDA - What's New: Drugs RSS Feed Published on 2022-05-17 By FDA
Colorful Products Corporation - 624415 - 05/10/2022
Source: FDA - What's New: Drugs RSS Feed Published on 2022-05-17 By FDA
Specialty Process Labs LLC - 624281 - 05/03/2022
Source: FDA - What's New: Drugs RSS Feed Published on 2022-05-17 By FDA
Assessing User Fees Under the Generic Drug User Fee Amendments of 2017
Source: FDA - What's New: Drugs RSS Feed Published on 2022-05-17 By FDA
Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endometrial Neoplasms, Date of authorisation: 17/07/2015, Revision: 44, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-05-17
Human medicines European public assessment report (EPAR): Selincro, nalmefene, Alcohol-Related Disorders, Date of authorisation: 24/02/2013, Revision: 13, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-05-17
Human medicines European public assessment report (EPAR): Remsima, infliximab, Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Psoriasis;Crohn Disease;Arthritis, Rheumatoid, Date of authorisation: 10/09/2013, Revision: 28, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-05-17
Human medicines European public assessment report (EPAR): Lumigan, bimatoprost, Glaucoma, Open-Angle;Ocular Hypertension, Date of authorisation: 08/03/2002, Revision: 36, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-05-17
Human medicines European public assessment report (EPAR): Bimzelx, bimekizumab, Psoriasis, Date of authorisation: 20/08/2021, Revision: 1, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-05-17
Human medicines European public assessment report (EPAR): Leflunomide Zentiva (previously Leflunomide Winthrop), leflunomide, Arthritis, Rheumatoid;Arthritis, Psoriatic, Date of authorisation: 08/01/2010, Revision: 18, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-05-17
Human medicines European public assessment report (EPAR): Deferasirox Mylan, deferasirox, Iron Overload;beta-Thalassemia, Date of authorisation: 26/09/2019, Revision: 7, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-05-17

Предыдущие записи

Тема: Scaffold от Danny Cooper.